Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00657
|
|||||
| Drug Name |
Cholic acid
|
|||||
| Synonyms |
(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 3,7,12-Trihydroxycholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; BHQCQFFYRZLCQQ-OELDTZBJSA-N; CHEBI:16359; CHEMBL205596; Cholalic acid; Cholalin; Cholic acid [USAN]; Cholic acid, 5beta-; Cholsaeure; Colalin; G1JO7801AE; HSDB 982; NSC-6135; NSC6135; UNII-G1JO7801AE; cholate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Peroxisomal disorders [ICD11: 5C57.0] | Approved | [1] | |||
| Synthesis disorders [ICD11: 5C52.10] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H40O5
|
|||||
| Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
|
|||||
| InChI |
InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
|
|||||
| InChIKey |
BHQCQFFYRZLCQQ-OELDTZBJSA-N
|
|||||
| CAS Number |
CAS 81-25-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 408.6 | Topological Polar Surface Area | 98 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11110315
, 14757556
, 15277848
, 17422064
, 24423691
, 24423929
, 24892356
, 24893153
, 26717723
, 26717726
, 26717727
, 26737120
, 26737126
, 26737128
, 26750105
, 26750407
, 26750412
, 26750415
, 26750420
, 26750424
, 30424718
, 3135999
, 3963
, 4266387
, 46507063
, 47193710
, 47662491
, 49700787
, 50452100
, 53787750
, 53789207
, 56313736
, 56437567
, 56437568
, 57399957
, 584143
, 607109
, 72129
, 7886587
, 81067251
, 81091088
, 8145669
, 822057
, 841391
, 85279435
, 85285851
, 85285861
, 85285865
, 85285871
, 9376190
|
|||||
| ChEBI ID |
CHEBI:16359
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASBT | Transporter Info | Apical sodium-dependent bile acid transporter | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [6] | ||
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [7] | ||
| References | ||||||
| 1 | Cholic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69. | |||||
| 3 | Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83. | |||||
| 4 | Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75. | |||||
| 5 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 6 | Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. | |||||
| 7 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.